AEE-788 is a dual EGFR/HER2 and VEGFR inhibitor developed to suppress tumor growth and angiogenesis; it also inhibits ERBB4 (HER4) with an IC50 of 0.16 μM, suggesting potential modulation of ERBB4 signaling [104]. Here, ERBB2 is linked to neoplasm.